FDA has approved Eli Lilly's Kisunla as the second drug that can slightly slow down the progression of Alzheimer's disease. With an approval for mild or early cases of dementia, the drug is a laboratory-made antibody administered via IV, targeting amyloid plaque buildup in the brain. The delay in cognitive decline is only about seven months, and patients need to weigh the benefits against potential risks like brain swelling. Despite concerns about long-term use, doctors see this approval as a significant step after decades of failed treatments. The drug's approval comes after an 18-month study showing patients had a 22% slower decline in memory and cognitive abilities than those on a placebo. The drug offers the advantage of being stopped if patients respond well, potentially reducing costs and safety risks. Logistical hurdles and financial concerns have slowed the rollout of similar drugs, but physicians are optimistic about having more options to help their patients with Alzheimer's.